Contact information
Department I of Internal Medicine
University Hospital of Cologne
CECAD Research Center
University of Cologne
Kerpener Straße 62
50937 Cologne
CV
Academic education
| 2009 - 2015 | Medical School, RWTH Aachen University, Germany |
| 2020 - 2024 | PhD Thesis, University of Cologne, Germany |
| 2012 - 2016 | MD Thesis, Department of Anatomy and Cell Biology, RWTH Aachen University, Germany |
Scientific degrees
| 2025 | Habilitation, Medical Faculty, University of Cologne, Germany |
| 2024 | PhD, Interdisciplinary Program Molecular Medicine at the University of Cologne, Germany |
| 2016 | MD Thesis, Department of Anatomy and Cell Biology, RWTH Aachen University, Germany |
Scientific career
| 2024 - present | Group leader, CECAD Research Center, University of Cologne, Germany |
| 2024 | Board certification in Internal Medicine, Hematology and Oncology, Germany |
| 2021 - 2023 | Postdoctoral fellow, Francis Crick Institute, London, United Kingdom |
| 2016 - 2024 | Clinical training, University Hospital of Cologne, Germany |
Honors/ Awards/ Memberships
| 2025. | EHA-ASH Translational Research Training in Hematology (TRTH) scholar |
| 2024 | Max-Eder Junior Research Group Program (German Cancer Aid) |
| 2023 | American Society of Hematology Abstract Achievement Award |
| 2023 | Selected for the German Lymphoma Alliance (GLA) Mentoring Program |
| 2022 | Translational Team Science Award by the US Department of Defense |
| 2022 | American Society of Hematology Abstract Achievement Award |
| 2021 | GLA Award „Lymphoma Clinical Research“ |
| 2020 | R01 grant “Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma” |
| 2019 | American Society of Hematology Abstract Achievement Award |
| 2018 | Mildred-Scheel-Postdoctoral scholarship (German Cancer Aid) |
| 2016 | Research grant of the LMU Munich (Förderprogramm für Forschung und Lehre/FöFoLe) 2014 Research grant of Friedrich Baur Stiftung |
Publications
-
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial
In patients with chronic lymphocytic leukemia, Richter transformation (RT) reflects the development of an aggressive lymphoma that is associated with poor response to chemotherapy and short survival. We initiated an international, investigator-initiated, prospective, open-label phase 2 study in…
-
Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range from 2 to 10%. The aim of this analysis is to report the frequency, characteristics and outcomes of pts with RT enrolled in trials of the…
-
High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia
In chronic lymphocytic leukemia (CLL), presence of complex karyotype (CKT; ie, $3 chromosomal abnormalities in $2 meta-phases) has adverse prognostic significance.1-5 The impact of targeted agents on CLL patients with CKT has been analyzed retrospectively and mostly in patients with…
-
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
Background The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with CLL and coexisting conditions is not known. Methods In this open-label, phase 3 trial, we investigated…